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CRISPR-Cas9 systems provide a platform for high efﬁciency genome editing that are enabling innovative
applications of mammalian cell engineering. However, the delivery of Cas9 and synthesis of guide RNA
(gRNA) remain as steps that can limit overall efﬁciency and ease of use. Here we describe methods for
rapid synthesis of gRNA and for delivery of Cas9 protein/gRNA ribonucleoprotein complexes (Cas9 RNPs)
into a variety of mammalian cells through liposome-mediated transfection or electroporation. Using
these methods, we report nuclease-mediated indel rates of up to 94% in Jurkat T cells and 87% in induced
pluripotent stem cells (iPSC) for a single target. When we used this approach for multigene targeting
in Jurkat cells we found that two-locus and three-locus indels were achieved in approximately 93%
and 65% of the resulting isolated cell lines, respectively. Further, we found that the off-target cleavageene editing
ransfection
ultiplex
rate is reduced using Cas9 protein when compared to plasmid DNA transfection. Taken together, we
present a streamlined cell engineering workﬂow that enables gRNA design to analysis of edited cells in
as little as four days and results in highly efﬁcient genome modulation in hard-to-transfect cells. The
reagent preparation and delivery to cells is amenable to high throughput, multiplexed genome-wide cell
engineering.
ublis© 2015 The Authors. P
. Introduction
CRISPR-Cas9mediatedgenomeengineeringenables researchers
o modify genomic DNA in vivo directly and efﬁciently (Cho et al.,
013a; Mali et al., 2013; Jiang et al., 2013;Wang et al., 2013). Three
omponents (Cas9, mature crRNA and tracrRNA) are essential for
unctional activity. Although the mature crRNA and tracrRNA can
e synthesized chemically, the quality of the synthetic RNA is not
ufﬁcient for in vivo cell engineering due to the presence of trun-
ated by-products (data not shown). Therefore, templates for the
ature crRNA and tracrRNA or a combined single gRNA are often
loned into a Cas9 expression plasmid or built into separate plas-
ids driven by either U6 or H1 promoters for transcription after
ransfectionofmammaliancells (Conget al., 2013;Mali et al., 2013).
owever the plasmids have been shown to have toxicity in some
Abbreviations: CRISPR, clustered regularly interspaced short palindromic
epeats; CAS9, CRISPR associated protein; gRNA, guide RNA; crRNA, CRISPR RNA;
racrRNA, trans-activating crRNA.
∗ Corresponding author. Tel.: +1 760 476 6068; fax: +1 760 268 7477.
E-mail address: jason.potter@thermoﬁsher.com (J. Potter).
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ttp://dx.doi.org/10.1016/j.jbiotec.2015.04.024
168-1656/© 2015 The Authors. Published by Elsevier B.V. This is an open access article
/).hed by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
cell lines (Kim et al., 2014). Recently, the use of Cas9 delivered as
mRNA has led to increases in the rate of genomic cleavage in some
cells. For example, a mixture of Cas9 mRNA and a single species
of gRNA were co-injected into mouse embryonic stem (ES) cells
resulting in biallelicmutations in 95%of newbornmice (Wanget al.,
2013). To make guide RNA, often a linearized plasmid containing
the T7 promoter and the gRNA sequence is used directly or a linear
template is created via PCR ampliﬁcation of the targeting sequence
from a plasmid. If a 5′ T7 promoter does not appear in the plas-
mid, it is often added at this step and the resulting PCR product
can be used in an in vitro transcription reaction (Jinek et al., 2012;
Wanget al., 2013).Alternatively, a syntheticDNA fragment contain-
ing a T7 promoter, crRNA and tracrRNA can be used as a template
to prepare a gRNA by in vitro transcription. Overall, these repre-
sent a labor-intensive and time-consuming workﬂow, which led
us to seek a simpler method to synthesize high quality gRNA. To
that, we describe here a streamlined modular approach for gRNA
production in vitro. Starting with two short single stranded oligos,
the gRNA template is assembled in a ‘one pot’ PCR reaction. The
product is then used as template in an in vitro transcription (IVT)
reaction which is followed by a rapid puriﬁcation step, yielding
transfection-ready gRNA in as little as four hours.
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
iotech
t
d
c
a
(
k
i
p
ﬁ
t
e
p
c
r
h
t
2
n
p
w
p
i
r
g
2
F
e
i
g
a
e
ﬁ
g
c
‘
s
w
r
2
h
r
d
t
f
t
t
P
s
w
t
m
t
l
e
f
2
2
EX. Liang et al. / Journal of B
To streamline the cell engineering workﬂow further, we sought
o eliminate any remaining cellular transcription or translation by
irectly introducing Cas9 protein/gRNA ribonucleoprotein (RNP)
omplexes directly to the cells. Microinjection of Cas9 protein
nd gRNA complexes into C. elegans was ﬁrst described in 2013
Cho et al., 2013b) and was subsequently used to generate gene-
nockout mice and zebraﬁsh with mutation rates of up to 93%
n newborn mice (Sung et al., 2014). Following that report, Cas9
rotein/gRNA RNP complexes were delivered into cultured human
broblasts and induced pluripotent stem cells (iPSC) via elec-
roporation with high efﬁciency and relatively low off-target
ffects (Kim et al., 2014). In that study, a large amount of Cas9
rotein (4.5–45g) and gRNA (6–60g) were necessary for efﬁ-
ient genome modiﬁcation (up to 79% indel efﬁciency). Another
ecent study delivered Cas9/gRNA RNPs along with donor DNA for
omology directed repair into HEK293T, human primary neona-
al ﬁbroblasts and human ESCs cells via electroporation (Lin et al.,
014). Here also, large amounts of Cas9 protein (4.8–16g) were
ecessary for efﬁcientmodiﬁcation.Most recently, delivery of Cas9
rotein-associated gRNA complexes via liposomeswas reported, in
hich RNAiMAX was used to deliver Cas9:sgRNA nuclease com-
lexes into cultured human cells and into the mouse inner ear
n vivo with up to 80% and 20% genome modiﬁcation efﬁciency,
espectively (Zuris et al., 2015).
The CRISPR/Cas system has been demonstrated as an efﬁcient
ene-targeting tool for multiplexed genome editing (Wang et al.,
013; Kabadi et al., 2014; Sakuma et al., 2014; Cong et al., 2013).
or example, co-transfections of mouse ES cells with constructs
xpressing Cas9 and three sgRNAs targeting Tet1, 2, and 3 resulted
n 20% of cells having mutations in all six alleles of the three
enes based on restriction fragment length polymorphism (RFLP)
ssay (Wang et al., 2013). Lentiviral delivery of a single vector
xpressing Cas9 and four sgRNAs into primary human dermal
broblasts resulted in about 30% simultaneous editing of four
enomic loci among ten clonal populations based upon genomic
leavage detection assays (Kabadi et al., 2014). In one recent study,
all-in-one’ expression vectors containing seven guide RNA expres-
ion cassettes and a Cas9 nuclease/nickase expression cassette
ere delivered into 293T cells with genome cleavage efﬁciency
anging from 4 to 36% for each individual target (Sakuma et al.,
014). In general, the efﬁciency of editing multiple genes in the
uman genome using plasmid-based delivery methods remains
elatively low which subsequently increases the workload for
ownstream clonal isolation.
In this study, we developed an in vitro gRNA production sys-
em and used a systematic approach to optimize the conditions
or delivery of Cas9:gRNA complexes via lipid-mediated transfec-
ion or electroporation. A variety of mammalian cell lines were
ested, including primary cells and other hard-to-transfect cells.
lasmidDNA,mRNAandCas9protein transfectionswere evaluated
ide by side. Using Cas9 protein transfection via electroporation,
e achieved superior genome editing efﬁciencies even in hard-
o-transfect cells. In addition, we explored the genome editing of
ultiple targets simultaneously using the Cas9 RNPs delivery sys-
em described here. We found that delivery of Cas9 RNPs not only
ed to high indel production at single locus, but supports highly
fﬁcient biallelic modulation of at least two genes in a single trans-
ection.
. Materials and methods.1. Materials
293FT cells, Gibco® Human Episomal iPSC line, mouse
14Tg2a.4 embryonic stem cells, primary human keratinocytesnology 208 (2015) 44–53 45
cells neonatal, inactivated embryonic ﬁbroblasts, DMEM medium,
RPMI 1640medium, IMDM,McCoy5Amodiﬁedmedium,DMEM/F-
12, KnockOutTM DMEM, Fetal Bovine Serum (FBS), KnockoutTM
Serum Replacement, Non-Essential Amino Acid solution, basic
ﬁbroblast growth factor, Collagenase IV, TrypLETM Express Enzyme,
Geltrex, Opti-MEM Medium, Essential 8TM medium, StemPro®-
34 SFM Complete Medium, FluoroBriteTM DMEM, recombinant
human leukemia inhibitory factor, GeneArt® Genomic Cleav-
age Detection Kit (GCD), Lipofectamine® 2000, Lipofectamine®
3000, Lipofectamine® RNAiMAX, Lipofectamine® MessengerMAX,
GeneArt®CRISPRNucleaseVectorwithOFPReporter, 2%E-Gel®EX
Agarose Gels, PureLink® PCRMicro Kit, TranscriptAid T7High Yield
Transcription Kit, MEGAclearTM Transcription Clean-Up Kit, Zero
Blunt® TOPO® PCR Cloning Kit, PureLink® Pro Quick96 Plasmid
Puriﬁcation Kit, Qubit® RNA BR Assay Kit, TRA-1-60 Alexa Fluor®
488 conjugated antibodies, SSEA4 Alexa Fluor®647, and Phusion
FlashHigh-FidelityPCRMasterMixwere fromThermoFisher Scien-
tiﬁc. Jurkat T cells and K562 cells were obtained from the American
Type Culture Collection (ATCC). CD34+ cord blood cells were pur-
chased from AllCells. A549 cells, U-2 OS cells, Neuro-2a (N2A) cells
were purchased from ATCC. MEF feeder cells and ROCK inhibitor
Y-27632 were purchased from EMD Millipore. Monoclonal Cas9
antibody was ordered from Diagenode. Recombinant Cas9 protein
with a NLS was initially puriﬁed as described (Kim et al., 2014) and
later obtained from Thermo Fisher Scientiﬁc. All oligonucleotides
used for gRNA synthesis and genomic cleavagedetectionwere from
Thermo Fisher Scientiﬁc (Table S1).
2.2. One-step synthesis of gRNA template
The 80bp cr/tracrRNA constant region was PCR ampliﬁed from
the GeneArt® CRISPR Nuclease Vector (1ng) using the Constant
Forward and Universal Reverse oligos (10M) and puriﬁed via
agarose gel extraction. The concentration of PCR product wasmea-
sured by Nanodrop (Thermo Fisher Scientiﬁc) and the molarity
was calculated based on the molecular weight of 49.6 kDa. To
prepare a mixture of oligonucleotides, the 80bp cr/tracrRNA PCR
product (0.15M) was mixed with universal forward and reverse
oligos (10M) aswell as target-speciﬁc forward and reverse oligos
(0.3M).
For each target locus, 2 oligonucleotides that recreate the target
sequence and share complementary with the bordering T7 pro-
moter and 80bp cr/tracr constant region were designed (Fig. 2A).
The forward oligo (Target F1) contains the 18 base T7 promoter
sequence as well as the ﬁrst 16 bases of the target and the reverse
oligo (Target R1) contains the reverse complement of the ﬁrst
15 bases of the cr/tracr constant region and the last 19 bases of
the target (Table 1s). To set up the synthesis of gRNA template,
aliquots of the pooled oligonucleotides were added to a Phusion
Flash High-Fidelity PCR Master Mix and ampliﬁed using manufac-
turer’s recommended reaction conditions. The PCR product was
analyzed by a 2% E-Gel® EX Agarose Gel, followed by puriﬁca-
tion using Purelink® PCR micro column. The gRNA template was
eluted with 13l water and the concentration was determined by
Nanodrop instrument. To determine the error rate, the PCR product
was cloned into Zero Blunt® TOPO® vector, followed by plasmid
DNA isolation and sequencingwith a 3500xlDNAanalyzer (Thermo
Fisher Scientiﬁc).
2.3. In vitro transcriptionThe in vitro transcriptionof gRNA templatewas carriedoutusing
TranscriptAid T7 High Yield Transcription Kit using the manufac-
turer’s recommended conditions. The gRNA product was puriﬁed
using MEGAclearTM Transcription Clean-Up kit as described in the
46 X. Liang et al. / Journal of Biotech
Table 1
Comparison of plasmid DNA, Cas9 mRNA/gRNA and Cas9 RNP transfection and
resulting editing efﬁciencies as measured by GCD assay in a variety of cell lines.
Cell lines Plasmid mRNA Protein
Lipid Electro Lipid Electro Lipid Electro
HEK293FT 49 49 70 40 51 88
U2OS 15 50 21 24 18 70
Mouse ESCs 30 45 45 20 25 70
Human ESCs (H9) 0 8 20 50 0 64
Human iPSCs 0 20 66 32 5 87*
N2A 66 75 66 80 66 82
Jurkat 0 63 0 42 0 94*
K562 0 45 0 27 0 72
A549 15 44 23 29 20 66
Human Keratinocytes
(NHEK)
0 30 0 50 0 35
Human Cord Blood
Cells CD34+
n/a 0 n/a 0 n/a 24
Note:
(1) gRNA targets are HPRT for human cell lines and Rosa 26 for mouse cell lines.
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anual. The concentration of RNA was determined using Qubit®
NA BR Assay Kit.
.4. Mammalian cell culture
HEK 293FT, A549 and N2A cells were maintained in DMEM
edium supplemented with 10% FBS. U2OS cells were main-
ained in McCoy 5A modiﬁed medium supplemented with 25mM
EPES and 10% FBS. Jurkat T cells were propagated in RPMI
edium containing 10% FBS. K562 cells were cultured in IMDM
edium supplemented with 10% FBS. Human ESCs (H9) were cul-
ured in Essential 8TM medium on tissue culture dishes coated
ith Geltrex® hESC-qualiﬁed reduced growth factor basement
embrane matrix. After thawing, cells were passaged 2–3 times
efore using for transfection. Feeder-dependent human episo-
al iPSC were cultured on mitotically inactivated MEF feeder
ells in human ESC (hESC) media containing 20% KnockoutTM
erum Replacement, 10M Non-Essential Amino Acid solution,
5M 2-Mercaptoethanol, and 4ng/ml basic ﬁbroblast growth
actor in DMEM/F-12. iPSC cultures were maintained with daily
edia changes and were passaged regularly using Collagenase
V. Mouse E14Tg2a.4 embryonic stem cells were cultured on
ouse (strain ICR) inactivated embryonic ﬁbroblasts in the pres-
nce of recombinant human leukemia inhibitory factor (LIF)
n mouse ESC medium consisting of KnockOutTM DMEM 15%
mbryonic stem cell–qualiﬁed Fetal Bovine Serum, 1× MEM Non-
ssential Amino Acids Solution, 1× GlutaMAXTM Supplement,
× 2-mercaptoethanol, and 10ng/mL LIF. Before transfection,
ells were adapted to feeder-free conditions and maintained
n attachment-factor-coated plates in mouse ESC-conditioned
edium. When setting up the experiments for transfections,
×105 cells were plated per well in a 24-well tissue culture dish
oated with attachment factor. CD34+ cord blood cells were cul-
ured using StemPro®-34 SFM Complete Medium supplemented
ith 100ng/mL of SCF, 50ng/mL of IL-3 and 25ng/mL of GM-CSF.
rimary human keratinocytes cells neonatal (HEKn) were grown
n a tissue culture dish treated with Coating Matrix Kit in EpiLife
edium containing 60M of calcium chloride. Cells were grown
or three passages before using for experiments. All cultures were
aintained in 5% CO2 at 37 ◦C in a humidiﬁed incubator. Prioro transfection, adherent cells were detached with Gibco TrypLE
elect Enzyme and then resuspended in the appropriate growth
edia.nology 208 (2015) 44–53
2.5. Lipid-mediated cell transfection
One day prior to transfection, the cells were seeded in a 24-well
plate at a cell density of 1–2×105 cells per well.
For plasmid DNA transfection, 0.5g DNA was added to 25l
of Opti-MEM medium, followed by addition of 25l of Opti-MEM
containing 2l of Lipofectamine 2000. The mixture was incubated
at room temperature for 15min and then added to the cells.
For Cas9 mRNA transfection, 0.5g Cas9 mRNA (Thermo Fisher
Scientiﬁc) was added to 25l of Opti-MEM, followed by addition
of 50–100ng gRNA. Meanwhile, 2l of either Lipofectamine 3000,
MessengerMax or RNAiMAX was diluted into 25l of Opti-MEM
and then mixed with mRNA/gRNA sample. The mixture was incu-
bated for 15min prior to addition to the cells.
For Cas9 protein transfection, 500ng of puriﬁed Cas9 protein
was added to 25l of Opti-MEM medium, followed by addition of
120ng gRNA. The molar ratio of gRNA to Cas9 protein was kept at
approximately 1 to 1.2: 1. The sample wasmixed by gently tapping
the tubes a few times and then incubated at room temperature for
10min. To a separate test tube, 2l of Lipofectamine RNAiMAX,
MessengerMax, or 3000 was added to 25l of Opti-MEM medium.
The diluted transfection reagent was transferred to the tube con-
taining Cas9 protein/gRNA complexes, followed by incubation at
room temperature for 15min and then added to the cells.
In each case, the entire solution was added to the cells in
a 24-well plate and mixed by gently swirling the plate. The
plate was incubated at 37 ◦C for 48h in a 5% CO2 incubator. The
percentage of locus-speciﬁc indel formation was measured by
GeneArt® Genomic Cleavage Detection Kit (GCD). The band inten-
sities were quantitated using the Alpha Imager software (Bio-Rad).
Each cell line was tested with each version of Lipofectamine (3000,
RNAiMAX, and MEssengerMAX). The lipid that resulted in highest
cleavage efﬁciency is listed in Table S2.
2.6. Electroporation
For suspension cells, such as Jurkat T cells, K562 cells or CD34+
human cord blood cells, 1–2×105 cells were used per electropo-
ration using Neon® Transfection System 10L Kit (Thermo Fisher
Scientiﬁc). For adherent A549, U2OS and N2A cells, 5×104 cells
were used per electroporation. For adherent HEK293FT, mESC,
hESC, human iPSC, A549, and NHEK cells, 1×105 were used per
electroporation.
To maximize the genome cleavage efﬁciency, the Neon 24 opti-
mization protocol was applied according to the manufacturer’s
instruction. To set up a master mix, 24g of puriﬁed Cas9 pro-
tein was added to 240l of Resuspension Buffer R provided in the
kit, followed by addition of 4.8g of gRNA. The mixture was incu-
bated at room temperature for 10min. Meanwhile, 4.8×106 cells
were transferred to a sterile test tube and centrifuged at 500× g for
5min. The supernatant was aspirated and the cell pellet was resus-
pended in 1ml of PBS without Ca2+ andMg2+. Upon centrifugation,
the supernatant was carefully aspirated so that almost all the PBS
buffer was removed with no or minimum loss of cells. The Resus-
pension Buffer R containing the Cas9 protein/gRNA complexes was
then used to resuspend the cell pellets. A 10l cell suspension was
used for each of the 24 optimization conditions, which varied in
pulse voltage, pulse width and the number of pulses. The electro-
porated cells were transferred immediately to a 24well containing
0.5ml of the corresponding growth medium for each cell line and
then incubated for 48h in a 5% CO2 incubator. The cells were har-
vested by centrifugation and then washed once with PBS, followedhigher amount of Cas9 protein (1.5–2g) and gRNA (300–400ng)
could be applied to further increase the genome editing efﬁciency
if needed.
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Each cell line was tested for with the Neon 24 optimization
rotocol. Speciﬁc electroporation conditions that resulted in the
ighest cleavage efﬁciency are listed in Table S2.
For each target in the multiplexing assays, 1–2g of Cas9
rotein and200–400ngof gRNA (maintaining a1:1 ratio)werepre-
ncubated separately in Resuspension Buffer R for 10min at room
emperature prior tomixingwith the cell pellet for electroporation.
For clonal isolation, the cell number of transfected cells was
ounted upon 48h incubation, followed by a serial of dilution to
6 well plates with a cell density of 10–20 cells per plate based
n the cell count. After clonal expansion for three weeks, cells
rom each individual well were harvested, followed by PCR ampli-
cation of the target locus. The PCR fragments were then cloned
sing a TOPO vector and transformed into TOP10 competent cells.
pproximately 8E. coli colonieswere randomlypicked for sequenc-
ng for each individual target locus. The single cell population was
etermined by the homogeneity of sequences for each allele. Sin-
le cells containing bi-allelic mutations on all desired targets were
onsidered homozygotic indels. Downstream sequence analysis to
onﬁrm frame-shift induced stop codon introductionwas not done.
For transfectionof feeder free adaptationof iPSC, feederdepend-
nt iPSC were grown to 80% conﬂuence prior to harvest with
ollagenase. Following removal of the cell clusters from the feeder
ayer, they were gravity sedimented to prevent MEF contamina-
ion. The cell clusters were then seeded on to tissue culture dishes
oated with Geltrex® in MEF conditioned media supplemented
ith 4ng/ml bFGF. MEF conditioned media was produced using
nactivated feeder cells,whichwas harvested on 7 continuous days,
terile ﬁltered and frozen until usage. The cultures were allowed to
each80–90% conﬂuence. Thedayprior to transfection, the cultures
ere pretreated with 5M ROCK inhibitor Y-27632. On the day of
arvest the cultures were inspected for signs of differentiation and
ny contamination differentiated cells were removed via micro-
issection. The cultures were washed once with DPBS and then
arvestedusingTrypLETM ExpressEnzyme. Single cells suspensions
ere counted using the Countess® automated cell counter. Follow-
ng transfections, the cells were seeded onto multi-well (24 well)
issue culture dish coated with Geltrex® and incubated overnight
ith MEF conditioned media containing 5M ROCK. Media was
eplaced daily, without ROCK inhibitor, prior to analysis.
.7. Cell surface immunostaining
To ensure maintenance of pluripotency post transfection and
enome editing, iPSC cells were tested for expression of cell sur-
ace markers of self-renewal. The wells to be probed were washed
ith DMEM/F12 basal media. TRA-1-60 Alexa Fluor® 488 conju-
ated antibodies and SSEA4 Alexa Fluor®647 were multiplexed in
asal DMEM/F-12 media. Both antibodies were added at a con-
entration of 2l of each antibody into 0.5ml of pre-warmed
MEM/F-12media and incubated at 37 ◦C for 45min. Following the
ncubation, the antibody solution was removed and the wells were
ashed twicewithDMEM/F-12. Prior to observation themediawas
xchanged with pre-warmed FluoroBriteTM DMEM. Images were
aken using a Zeiss Axiovision microscope using a FITC and Cy5
aser/ﬁlter combination.
.8. Analysis of pluripotency markers
Cultures were detached and dissociated using TrypLETM Select
nd trituration. Single cell suspensions were incubated with TRA-
-60 Alexa Fluor® 488 conjugated antibodies and SSEA4 Alexa
luor®647 for 1h at room temperature with gentle agitation.
wo microliters (50× concentration, as supplied) of each antibody
ere added to 0.5mL of DMEM/F-12. Following the incubation,
he cells were centrifuged and washed once with Dulbecco’snology 208 (2015) 44–53 47
Phosphate-Buffered Saline (DPBS). After the removal of the DPBS
wash, the pelleted cells were gently re-suspended in 1ml of DPBS
and stained through a strainer capped tube. The cells were then
measured for the expression of both markers using the Attune®
Acoustic Focusing Cytometer and the data was analyzed using
FlowJo software.
2.9. Western Blot analysis
HEK293FT cells were transfectedwith either Cas9 plasmid DNA,
mRNA or protein as described above. Mouse ESCs were electropo-
rated with Cas9 RNPs as described above. Cells were harvested at
indicated times to performbothGCDassay andWestern Blot analy-
sis. The cell lysatewas fractionatedusing a4–12%NovexBis-tris gel.
The proteins were transferred to a PVDF membrane using an iBlot
following the manufacturer’s protocol. Upon blocking, the mem-
branewas incubated for 2hwithmonoclonalmouse Cas9 antibody
at 1:3000 dilution. Afterwashing, themembranewas incubated for
1hour with rabbit anti-mouse antibody-HRP conjugate at 1:2000
dilution. Upon extensive washing, the membrane was developed
with Pierce ECL reagent, followed by imaging using a Fuji imager
LAS 4000 instrument.
3. Results
3.1. Three day cell engineering workﬂow
To streamline the genome engineering workﬂow, we sought to
simplify the gRNA synthesis procedure and shorten the time from
experimental design to initial analysis as much as possible. We
present a processwhere onday1, the researcher designs andorders
short DNA oligonucleotides and seeds the cells of interest for next
day transfection (Fig. 1).Upon receiving theoligonucleotidesonday
2, the researcher assembles the gRNA template in less than 1h by
‘one pot’ PCR. The resulting PCR product is then subjected to in vitro
transcription to synthesize gRNA in approximately 3h. Upon asso-
ciation of gRNA with puriﬁed Cas9 protein, the Cas9 RNPs are used
to transfect cells via lipid-mediated delivery or electroporation. As
early as day 3 (24h post transfection), the cells can be harvested
for analysis of locus-speciﬁc genome modiﬁcation efﬁciency.
We used an online web tool to identify candidate 20 nt gRNA
target sequences for each loci (Beta Testing Version, Thermo Fisher
Scientiﬁc). A pair of 34 nt forward and reverse oligonucleotides
comprising each target sequence were designed as described. To
assemble theDNA template for gRNAproduction,we combined the
2 target speciﬁcoligos (Target F1/R1)withamixtureof the2univer-
sal oligos (Universal Forward/Reverse) and a puriﬁed PCR product
representing the constant non-targeting region of the full gRNA
(Fig. 2A). The oligonucleotide pool concentrations as well as the
PCR conditions were optimized such that the template was ampli-
ﬁed in less than 40min in a single tube with (Fig. 2B). The gRNA
template was used directly to prepare gRNA via in vitro transcrip-
tion (IVT). The resulting gRNA was puriﬁed, yielding high levels of
gRNA with low amounts of detectable by-products (Fig. 2C). This
approachwasvalidatedbysynthesisofmore than96distinct gRNAs
(unpublished results). To determine the error rate in the synthetic
gRNA DNA template, we cloned and sequenced the PCR fragments
and found that using this design approximately 7% of gRNA tem-
plates harboredmutations, mainly small deletions occurring at the
extreme 3′ end and 5′ ends of the mature template compared to
21% mutants with an alternative design of using long overlapping
oligonucleotides (Fig. 2D). Since all the mutations observed using
our design appeared to be due to errors in the oligonucleotides,
we next tried HPLC-puriﬁed universal forward and reverse primers
which further decreased the error rate to 3.6% with no mutations
48 X. Liang et al. / Journal of Biotechnology 208 (2015) 44–53
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Cas9 RNP) are performed on day 2. Genome cleavage assays carried out on days 3–
etected in the target region, whichwas similar to the 2% error rate
bserved with the control template prepared from an ‘all-in-one’
lasmid. Taken together, this optimized process facilitates the con-
ersion of a small set of DNA oligonucleotides into puriﬁed gRNA
n approximately 4h with an accuracy of up to 96% and no errors
etected in the targeting or Cas9 complexing (cr/tracrRNA) regions.
his level of accuracy should be sufﬁcient for routine screening
f gRNAs, but if a sequence veriﬁed gRNA is required the gRNA
emplate can easily be Topo cloned. Given that the process con-
ists solely of liquid handling PCR, transcription, and RNA isolation
teps, it is well suited for high throughput gRNA production and
creening.
.2. Liposome-mediated Cas9 protein transfection
To examine the activity of synthetic gRNA, we pre-complexed
uriﬁed synthetic IVT gRNA with Cas9 protein, hypothesizing that
reating complexes of puriﬁed gRNAs with Cas9 protein prior to
elivery to the cells might lead to higher genome editing efﬁciency
ue to the protection of the gRNAas it transits to the nucleus during
he transfectionprocess. To examine in vivo functionality of the sys-
em, human embryonic kidney (HEK293FT) cells were transfected
ith pre-complexed Cas9/gRNA ribonucleoproteins (Cas9 RNPs)
sing a set of cationic lipid reagents, followed by a GCD assay. The
ommonly-used plasmid DNA or RNA lipofectamine transfection
eagent had been shown to be able to deliver many proteins into
ells, so we tested several lipofectamine variants for their ability
o efﬁciently deliver Cas9 RNPs (Sells et al., 1995). Lipofectamine
000 and RNAiMAX outperformed Lipofectamine 2000 in HEK 293
ells (Figure S1), which is in agreementwith the recent ﬁnding that
NAiMAX performed better than Lipofectamine 2000 for delivery
f Cas9 RNPs with low cell toxicity (Zuris et al., 2014). We tested
he molar ratio of cas9 protein to gRNA and generally observed
hat cleavage activity plateaued at a 1:1 ratio (data not shown). For
rotein transfection, serum-freemedium is generally used to avoidds cells. Synthesis of gRNA and cell transfection with Cas9 protein/gRNA complex
serum protein inference. In this study however, we observed that
the completemediumcontaining 10% FBS could facilitate increased
protein transfection and genome modiﬁcation (Fig. 3A, panel a).
The efﬁciencies of genome editing via plasmid DNA, mRNA and
Cas9 RNP transfection were evaluated using three different target
loci, HPRT, AAVS and RelA. Plasmid DNA and mRNA were deliv-
ered into HEK293 cells by Lipofectamine 3000, whereas Cas9 RNPs
were delivered with RNAiMAX. The efﬁciencies of genome modi-
ﬁcation were similar among three target loci in DNA, mRNA and
Cas9 protein-transfected cells (Fig. 3A).
Nextwe examined the kinetics of genome cleavage by transfect-
ing cellswith either plasmidDNA,mRNA, or Cas9RNPs, followedby
GCD assays and western blot analysis of cell lysates. We observed
similar cleavage kinetics between Cas9 delivered as plasmid DNA,
mRNA and proteinwith efﬁcient cleavage seen at 24h and plateau-
ing at 48–72h post-transfection inHEK293 cells (Fig. 3B). However,
the kinetics of Cas9 RNP and mRNA encoded Cas9 appearance and
turnover inside the transfected cells was quite different from that
seen with Cas9 delivered via plasmid DNA. Measuring by western
blot (Fig. 3C), we found that Cas9 protein accumulated over time in
plasmid DNA-transfected cells, whereas the relatively low expres-
sion of Cas9 in mRNA-transfected cells seemed to peak as early
as four hours post transfection and remained relatively stable for
approximately 48hbefore diminishing. In theCas9RNP transfected
cells, the level of Cas9 protein peaked in at the ﬁrst time point,
then rapidly decreased and was barely detectable in our assay at
48h. As a control, the blot membrane was stripped and re-probed
with anti-actin antibody. Similar levels of actin expression were
observed among samples (data not shown).
Because of the observed faster protein depletion, we hypoth-
esized that the off-target cleavage activity for Cas9 RNP and
mRNA/gRNA transfectionwould be lower than that of plasmidDNA
transfection (Fu et al., 2013; Pattanayak et al., 2013; Hsu et al.,
2013). To test this, we targeted a locus (target site 3) in the VEGFA
gene which has been identiﬁed as having several high activity
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Fig. 2. Design and synthesis of gRNA. (A) Design of gRNA DNA template mix. Themixture consists of an 80bp PCR product encoding the cr/tracrRNA constant region, universal
forward and reverse primers, and 2 overlapping target-speciﬁc 34 nt DNA oligonucleotides (Target F1 and R1). (B) One-step PCR synthesis of gRNADNA template. Themixture
of oligonucleotides and PCR product were assembled in a single tube by PCR and the product was analyzed by agarose gel electrophoresis (Lanes 2 and 3). A gRNA DNA
template ampliﬁed from a plasmid served as control (Lane 1). (C) Aliquots of PCR product (Lanes 2 and 3) along with the plasmid derived control (Lane 1) were subjected
to in vitro transcription. The resulting product was analyzed by denaturing gel. (D) Analysis of gRNA DNA template sequence error rate. The gRNA DNA templates were
synthesized using the standard gene synthesis approach with a set of long oligonucleotides (Long). Alternatively, the oligonucleotide mixture described above was used
for PCR assembly. The two standard desalted universal forward and reverse primers (Short) were compared to HPLC or PAGE-puriﬁed primers (Short/HPLC). The synthetic
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olonies were randomly picked for sequencing and the errors grouped by location.
ff-target sites (Fu et al., 2014) via Cas9DNA,mRNA, andRNP trans-
ection intoHEK293FT cells followedby genome cleavage and locus
equencing analysis. Among the six potential off-target sites that
ave been studied previously (OT3-1, OT3-2, OT3-4, OT3-9, OT3-17
nd OT3-18), only OT3-2 and OT3-18 were detected to harbor off-
arget mutation based on GCD analysis. Further analysis of locus
T3-2 by sequencing indicated that the ratio of indel mutation of
T3-2 over on-target inmRNAandCas9RNP transfected cellswas 2
old and 2.5 fold lower than that in DNA-transfected cells, respec-
ively. The ratio of indel mutation of OT3-18 over on-target was
.6 fold and 28 fold lower in mRNA or Cas9 RNP-transfected cells,control (Plasmid) were cloned into a TOPO vector. For each individual template, 96
respectively than in DNA-transfected cells (Fig. 3D). Nextwe tested
the effect of increased Cas9 RNP (maintaining a 1:1 molar ratio of
gRNA to protein) on off-target levels and observed that while on-
target editing efﬁciency increased with an increased dose of Cas9
RNP, reaching plateau at around 2g of Cas9 protein, the off-target
modiﬁcation at the OT3-T2 loci increased at a lower rate (Figure
S2). Taken together, these data suggest that Cas9 delivery asmRNA
and pre-complexed protein supports increased genomic cleavage
speciﬁcity compared with standard DNA plasmid transfection. In
a survey of 11 cell lines (Table 1, Table S2), Lipofectamine 3000
worked best for Cas9 plasmid delivery, while depending on cell
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Fig. 3. Lipid-mediated transfection. (A) Three separate genomic loci (HPRT, AAVS or RelA)were edited via Cas9 plasmidDNA,mRNAor protein using lipidmediated transfection
of HEK293FT cells. For the HPRT target, transfection was performed in the presence or absence of serum. For AAVS and RelA, serum was used and 2 concentrations of cas9
protein were tested. The percentage of edited cells (% indel) that resulted in an indel was determined using the GCD assay by quantitating the amount of uncut vs cut DNA
(arrow). (B) HEK293FT cells were transfected with either plasmid DNA, Cas9 mRNA/gRNA or Cas9 RNPs directed to the HPRT loci. Cell samples were taken at different time
points and analyzed by GCD assays. (C) Western Blot analysis of samples taken at different time points. (D) Off-target mutation of VEGFA T3 target caused by Cas9 plasmid
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oNA, mRNA or protein transfection. Percentages of on-target mutation as well as O
ineeither LipofectamineRNAiMAXorMessengerMAXworkedwell
or Cas9 mRNA or RNP delivery. However, with some cell lines no
onditions were found for efﬁcient Cas9 delivery.
.3. Electroporation-mediated Cas9 protein transfection
Many biologically and physiologically relevant cell lines, such
s patient derived iPSC and progenitor cells, are refractory to efﬁ-
ient transfection by lipid-based reagents. Any improvement in
he efﬁciency of genome modulation would facilitate isolation of
ppropriately engineered cells for experimentation and therapy so
e explored alternate means of delivering Cas9 RNPs and Cas9
RNA/gRNA formulations and their effect on indel generation.
sing Jurkat T cells as an initial model, we compared the delivery
f Cas9 and gRNA plasmid DNA, Cas9 mRNA/gRNA formulations
nd Cas9 RNPs using electroporationwith a Neon Transfection sys-
emand a24 condition optimizationprotocol (Fig. 4, Figure S3). Our
esults showed that, comparedwith plasmidDNA andmRNAdeliv-
ries, superior genome editing efﬁciency was achieved via delivery
f Cas9 RNPs with ∼90% HPRT locus-speciﬁc modiﬁcation undernd OT3-18 off-target mutations were determined by sequencing.
several electroporation conditions (Fig. 4A). The cleavage efﬁciency
wasdose-dependent, reachingamaximumof88%at approximately
1.5g Cas9 protein and 300ng gRNA per transfection (Fig. 4B).
After sequencing the cell pools, we found that actually 94% of tar-
get loci harboredmutations near the expected cleavage site located
around 3 bases upstream of the NGG PAM sequence. The majority
of mutations were distinct from each other with 75% insertion and
16% deletion.Whenwe tested the same optimization protocolwith
human iPSCs, the optimal conditions varied signiﬁcantly from the
Jurkat T settings (Figure S4A). The cleavage efﬁciency of the Cas9
RNP,was improved from62%at the standard1g/l Cas9RNP con-
centration to 89% at 3g/l Cas9 RNP (Figure S4B). We checked
the transfected iPSCs pluripotency markers SSEA4 and TRA-1-60
by ﬂow cytometry (Figure S4C) and observed only a small change
from 93% dual positive in the control to 85% after transfection with
Cas9 RNP.Whenwe sequenced the cell pools at the HPRT locus, we
saw an 88% indel rate and a different indel distribution from Jurkat
T of 32% insertion and 52% deletion with more large deletions and
smaller insertions (Table S3). Using the optimization protocol, we
surveyed the same 11 cell lines used previously for delivery of Cas9
X. Liang et al. / Journal of Biotechnology 208 (2015) 44–53 51
Fig. 4. Electroporation-mediated transfection. (A) Mastermix of plasmid DNA, Cas9 mRNA/gRNA or Cas9 protein/gRNA were used to electroporate Jurkat T cells using the
Neon 24 optimization protocol. The numbers 1–24 refer to different conditions which vary pulse voltage, pulse width and number of pulses (Figure S3). The percentage of
locus-speciﬁc genome cleavage was estimated 48-hour post transfection using a GCD assay. (B) Dose-dependent effect of genome editing. While keeping the ratio of Cas9
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lasmid, mRNA or RNPs and saw efﬁcient delivery in all cell lines
xcept for cord blood cells where only RNPs resulted inmeasurable
ndel formation (Table 1, Table S2). The speciﬁc pulse conditions
ariedwidely depending on cell line and construct. Overall, we saw
est results with Cas9 RNPs. Finally wemeasured the cleavage rate
nd turnover kinetics of the Cas9 RNPs inmouse ESCs and observed
hat cleavage could be detected within 4h, plateaued after 8h and
he protein appeared to be almost depleted by 12h (Figure S5).
.4. Targeting multiple loci in a single transfection
Given the high single-locus cleavage efﬁciency measured with
he Cas9 RNP system, we next wanted to test the ability to efﬁ-
iently lesion multiple genes in a single transfection. Here we
xamined the capability of multiplexing Cas9 RNP transfection at
hree loci (AAVS1, RelA and HPRT). After pooling and delivering
ultiple species of Cas9 RNP (differing only by gRNA target), we
ound that the efﬁciency of simultaneous editing of AAVS1/HPRT or
AVS1/RelA/HPRT lociwas signiﬁcantly greater at all loci compared
ith either plasmid or mRNA delivery of Cas9 (Fig. 5A and C). To
ain insight into themolecular level ofmultiplexing, we performed
ne round of clonal isolation by serial dilution. After clonal expan-
ion each of the loci was PCR ampliﬁed, followed by DNA cloning
nd sequencing. In the case of two gene editing, we found that all
f 16 isolated clonal cell lines harbored bi-allelic indel mutations
n single AAVS1 loci and 93.7% (15 of 16) of clonal cells harbored
ne allelic indel mutation at the HPRT locus as the HPRT target was
ocated on the X chromosome of a male Jurkat T cell line. Overall,
3.7% of the clonal cell populations carried indelmutations on both
he AAVS1 and HPRT loci (Fig. 5B). For multiplexing of three genes,
e performed three individual cell transfections and clonal isola-
ion with a total of 53 single cell lines analyzed. In this experiment,
0% and 65% of the clonal cell lines analyzed harbored bi-allelic
ndel mutations at the AAVS1 and RelA loci, respectively, whereas
0% of the clonal cells carried indel mutations at the single HPRT
ocus. Overall, 65% of the clonal cell lines harbored indel mutations
n all three targets at all 5 alleles (Fig. 5D). Further, 100% of the
urkat T cell clones were edited at least once, suggesting that the
ransfection efﬁciency reached nearly 100%. Taken together, Cas9
NP delivery via electroporation under the conditions used here
chieved exceptionally high mutagenesis frequencies. This repre-
ents a substantial improvement in Cas9-mediated genome editing
nd signiﬁcantly reduces the workload needed for clonal isolation
y signiﬁcantly reducing the number of cells thatmust be screened
n order to identify and isolate the desired cell line.ng protocol 5. Experiments were done in triplicate. The percentage of cleavage was
4. Discussion
The ability to easily modulate the sequence speciﬁcity of the
Cas9 nuclease by simply changing the 20 nucleotide targeting
sequence of the gRNA offers signiﬁcant versatility in delivery
options over other nucleases that have been utilized for genome
editing, such as zinc ﬁnger nucleases and TAL effectors. Now,
researchers are able to choose from cost-effective and rapid design
options by formulating the nuclease as either plasmid DNA, pre-
mademRNAor puriﬁed protein. The design versatility is enabled by
rapid production of the guide RNA component. Until recently, the
gRNA was generally produced via cloning of a template sequence
into a plasmid vector or vectors and expressing the Cas9 and gRNA
in vivo.Wedescribe a streamlinedprotocolwhere gRNAdesign and
template construction is facilitated by synthesis of two short single
stranded oligonucleotides. The oligonucleotides are incorporated
into gRNA templates via a short PCR reaction followed by conver-
sion to gRNA by in vitro transcription. Target-speciﬁc oligos can be
designed, ordered, and converted to puriﬁed gRNA in as little as
two days. On the second day, the gRNA is formulated with either
Cas9mRNA or protein, and immediately used to transfect cells. The
entireprocess consists completelyof liquidhandlingandenzymatic
reaction steps,whichmake it amenable to higher throughput gRNA
production and transfection in multi-well plates.
We compared the streamlined gRNA workﬂow across the three
delivery options and found that in general, Cas9 RNPs offered supe-
rior indel production efﬁciency in most of the cell lines we used as
a test bed. It is currently not clear why Cas9 RNP and total RNA
formulations perform as they do but a factor could be overall size
of the lipid complexes, the controlled complexing of the Cas9 pro-
tein and gRNA in vitro, the ability of Cas9 protein to protect the
gRNA from cellular degradation, and the elimination of DNA-based
cellular toxicity. In relation to plasmid delivery, Cas9 introduced
as a Cas9 RNP or mRNA appears in the cell at low but evidently
functional levels and is cleared rapidly. The rate of protein cas9
clearance and cleavage kinetics appears to be related to the cell
lines used as we saw faster evidence of cutting and faster clearance
in mouse ESCs than in HEK293FT cells. This variation in cleavage
kinetics is supported by previous results in K562where >20% cleav-
age activity was observed within 8h (Kim et al., 2014) and U2OS
where 7.8% cleavage activity was observed with the ﬁrst 3h (Zuris
et al., 2014). However there are differences in the amount of protein
used and the delivery method (electroporation or lipid-mediated)
and further study is needed. We also saw variations in how double
strand breaks at the same HPRT loci were repaired between Jurkat
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Fig. 5. Multiple gene editing in the human genome. Jurkat T cells were cotransfectedwith either a Cas9 plasmid pool, a Cas9mRNA/gRNA pool or Cas9 RNP complexes targeting
AAVS1 and HPRT targets (A) or AAVS, RelA and HPRT targets (C). GCD assays were performed for each locus at 48h post transfection. Cell aliquots were then subjected to
clonal isolation by serial dilution. After clonal expansion, each locus was PCR-ampliﬁed from each clonal cell line. The PCR product was then cloned into a plasmid vector and
the percentage of indel mutation was determined by sequencing of eight individual E. coli colonies. Quantitation of double mutants for AAVS1 and HPRT was based on 16
clonal cell lines (B), whereas quantitation of triple mutants of AAVS, RelA and HPRT was based on a total of 53 clonal cell lines derived from three independent experiments
(D). For individual loci, + + indicates homozygote wildtype, +/− heterozygote, and −/− indicates heterozygote knock out where each allele has a different indel. For multiple
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nock out of all alleles.
and human iPSCs. Our results along with previous work (Mali
t al., 2013; Wang et al., 2014), suggests that different cell lines
ay have variations in how they conduct NHEJ. The fast turnover
f cas9 RNP and mRNA compared to the long persistence of cas9
xpressed fromplasmid could reduce the opportunity for off-target
inding and cleavage. In addition,many off-target sites are cutwith
ower efﬁciency than the on-target site (Jinek et al., 2012). Previous
esearch (Kim et al., 2014; Zuris et al., 2014) also saw reduced off-
arget cleavage for Cas9 RNP compared to plasmid. Much progress
as beenmade to reduce or eliminate off-target cleavage in CRISPR
ystems, suchasuseof pairedCas9nickases anddimeric ‘deadCas9′
okI fusions, which has been shown to reduce off-target activity
y 50–1500-fold (Guilinger et al., 2014; Tsai et al., 2014). Perhaps
elivery of these tools via Cas9 RNPs would lead to even higher
peciﬁcity while retaining high activity levels.
In this work, we were also able to multiplex three Cas9 RNP
pecies targeting separate loci in Jurkat T cells while achieving
igh levels indel production at all three loci. Further, we observed
igh rates of biallelic modiﬁcation at two diploid alleles (AAVS1
nd RelA) in these experiments even when also modifying a third
aploid locus (HPRT) at similarly high levels. Taken together, the
igh rates of biallelic modiﬁcation in cell populations suggest
hat employing Cas9 RNP delivery would signiﬁcantly simplify the
orkﬂow by facilitating the selection of multigene knockout cell
ines from a single experiment. Additionally, the system could be
dapted by varying the dosages of individual Cas9 RNP species to
etter interrogate multigenic disorders.
We performed a survey of eleven commonly used mam-
alian cell lines comparing CRISPR delivery via plasmid, Cas9icates heterozygote knock out of at least one allele, and −/− indicates heterozygote
mRNA/gRNA, and Cas9 RNP (Table 1) and found that Cas9
mRNA/gRNA or Cas9 RNPs were superior to plasmid delivery in
all cell lines tested. Delivery of these reagents via electropora-
tion offered the highest target-speciﬁc indel production under the
conditions tested. In all but one case (NHEK cells), Cas9 RNP out
performed Cas9 mRNA/gRNA and in human CD34+ cord blood
cells, Cas9 RNP delivered via electroporation was the only method
that yielded a signiﬁcantly robust editing solution. With both
lipid-mediated transfection and electroporation, optimization of
transfection conditions for each cell line is necessary for achieving
the best cleavage efﬁciency.
5. Conclusion
We describe here a streamlined approach to the mammalian
genome engineering workﬂow that takes as few as three days to
modify mammalian genomes from CRISPR target design through
evaluation of genome editing. To achieve high mutagenesis efﬁ-
ciencies in hard-to-transfect cells, we used a systematic approach
to optimize transfection conditions where we compared deliv-
ery of CRISPR editing tools via plasmid DNA, Cas9 mRNA/puriﬁed
gRNA formulations, and pre-complexed Cas9 RNPs. We found Cas9
mRNA/gRNA and Cas9 RNP performance superior to ‘all-in-one’
plasmid DNA constructs in the variety of cell lines analyzed in this
work. Most likely due to the high efﬁciency of Cas9 RNP delivery,
we were able to efﬁciently modify the genome at multiple loci
simultaneously, thereby reducing the workload for downstream
clonal isolation in schemes where more than one gene knock-out
is desired. Further, we found that delivery of Cas9 RNPs to cell lines
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onsidered hard to transfect (Jurkat, iPSC, CD34+ ) via electropora-
ion could yield high levels of locus speciﬁc modiﬁcation.
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